RADX and RAD Related Headlines
Go Back- Radiopharm doses first patient in second RV-01 trial cohort
- Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors
- Radiopharm trial advances to higher dose in HER2+ cancer study
- Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial
- Radiopharm sets FDA meeting for RAD101 brain metastases trial design
- Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases
- Radiopharm Theranostics Reports Business Update
- Radiopharm raises up to $13M via US and Australian offerings
- Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan
- Radiopharm reports partial response in RAD204 cancer drug trial
- Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy
- Radiopharm RAD101 meets Phase 2b endpoint for brain metastases
- Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases
- Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
- International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on April 28, 2026
- Radiopharm Theranostics Reports Business Update
- Radiopharm presents early trial data for HER2-targeted cancer therapy
- Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer Research 2026
- Radiopharm moves to next dose level in cancer drug trial
- Radiopharm Theranostics Advances to Cohort 3 in 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial
- Radiopharm Theranostics partners with Siemens for RAD101 supply
- Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S.
- Radiopharm doses first patient in RAD 402 prostate cancer trial
- Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer
- Radiopharm Theranostics reports 90% success rate in brain imaging trial
- Radiopharm Theranostics Achieves Primary Endpoint In 90% of Patients At Second Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases
- Radiopharm Theranostics doses first patient in cancer drug trial
- Radiopharm Theranostics Doses First Patient in Phase 1/2a Clinical Study of BetaBart (RV-01)
- Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates
- Presenting on Emerging Growth Conference 89 Day 1 on January 21; Register to live stream
- RAD Increases Ownership in Radiopharm Ventures to 87.5%
- Radiopharm Theranostics Achieves Primary Endpoint in 92% of Patients at Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases
- Radiopharm Theranostics gets approval for prostate cancer drug trial
- Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 (KLK3-mAb with Tb161) in Advanced Prostate Cancer
- Radiopharm Theranostics Announces 50% Enrollment in Phase 2b Clinical Trial of RAD101 Imaging in Brain Metastases
- Radiopharm Theranostics advances to third cohort in cancer drug trial
- Radiopharm Theranostics starts enrollment of the Third Cohort of Phase 1 Dose Escalation Clinical Trial of 177Lu-RAD204
- International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025
RADX and RAD Related Press Releases
Go Back- Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors
- Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial
- Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases
- Radiopharm Theranostics Reports Business Update
- Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan
- Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy
- Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases
- Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
- International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on April 28, 2026
- Radiopharm Theranostics Reports Business Update
- Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer Research 2026
- Radiopharm Theranostics Advances to Cohort 3 in 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial
- Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S.
- Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer
- Radiopharm Theranostics Achieves Primary Endpoint In 90% of Patients At Second Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases
- Radiopharm Theranostics Doses First Patient in Phase 1/2a Clinical Study of BetaBart (RV-01)
- Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates
- Presenting on Emerging Growth Conference 89 Day 1 on January 21; Register to live stream
- RAD Increases Ownership in Radiopharm Ventures to 87.5%
- Radiopharm Theranostics Achieves Primary Endpoint in 92% of Patients at Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases
- Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 (KLK3-mAb with Tb161) in Advanced Prostate Cancer
- Radiopharm Theranostics Announces 50% Enrollment in Phase 2b Clinical Trial of RAD101 Imaging in Brain Metastases
- Radiopharm Theranostics starts enrollment of the Third Cohort of Phase 1 Dose Escalation Clinical Trial of 177Lu-RAD204
- International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025
RADX and RAD Related SEC Filings
Go Back- Form 6-K Radiopharm Theranostics For: Aug 28
- Form 6-K Radiopharm Theranostics For: Aug 27
- Form 6-K Radiopharm Theranostics For: Aug 26
- Form 6-K Radiopharm Theranostics For: Aug 20
- Form 6-K Radiopharm Theranostics For: Aug 17
- Form 6-K Radiopharm Theranostics For: Aug 13
- Form 6-K Radiopharm Theranostics For: Jul 24
- Form 6-K Radiopharm Theranostics For: Aug 03
- Form 6-K Radiopharm Theranostics For: Jul 31
- Form 6-K Radiopharm Theranostics For: Jul 28
- Form 6-K Radiopharm Theranostics For: Jul 28
- Form 6-K Radiopharm Theranostics For: Jul 27
- Form 424B5 Radiopharm Theranostics
- Form 6-K Radiopharm Theranostics For: Jul 24
- Form 424B5 Radiopharm Theranostics
- Form 6-K Radiopharm Theranostics For: Jul 22
- Form 6-K Radiopharm Theranostics For: Jul 03
- Form 6-K Radiopharm Theranostics For: Jun 30
- Form 6-K Radiopharm Theranostics For: Jun 03
- Form 3 Radiopharm Theranostics For: Mar 18 Filed by: Voliotis Dimitris
- Form 3 Radiopharm Theranostics For: Mar 18 Filed by: HOPPER PAUL
- Form 3 Radiopharm Theranostics For: Mar 18 Filed by: Laurita Aaron James
- Form 3 Radiopharm Theranostics For: Mar 18 Filed by: Donnelly Noel
- Form 3 Radiopharm Theranostics For: Mar 18 Filed by: Turner Ian Lawrence
- Form 3 Radiopharm Theranostics For: Mar 18 Filed by: Larkin Hester Denise
- Form 3 Radiopharm Theranostics For: Mar 18 Filed by: Canevari Riccardo
- Form 3 Radiopharm Theranostics For: Mar 18 Filed by: Goodwin Bruce Michael
